---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Weight management and incretin-based pharmacotherapy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Weight management and incretin-based pharmacotherapy. Topics: VA/DoD guideline: evidence-based weight management combined with other OSA treatment (weak for); ATS guideline: comprehensive lifestyle intervention (strong), antiobesity pharmacotherapy evaluation (conditional), and bariatric surgery referral (conditional); ATS guideline: literature search dates and pharmacotherapies reviewed; ACP guideline: weight loss for all adults with overweight or obesity and OSA (strong recommendation, low-quality evidence); 10 further topics. 14 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/weight-management-and-incretin-based-pharmacotherapy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Weight management and incretin-based pharmacotherapy

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Weight Management and Incretin-based Pharmacotherapy

<a id="topic-2.2.2.1.3-1"></a>

### VA/DoD guideline: evidence-based weight management combined with other OSA treatment (weak for)

> “20. For treatment of obstructive sleep apnea in patients with overweight or obesity, we suggest evidence-based weight management in combination with other treatments for obstructive sleep apnea. (See VA/DOD CPG on Management of Overweight and Obesity) Weak for”
> “An additional publication was identified that was not included in our literature review because it was published after the cutoff date for this guideline evidence synthesis.”
> “The Work Group is aware that on December 20, 2024, the FDA approved tirzepatide for the treatment of moderate to severe OSA in patients with obesity, to be used in combination with a reduced calorie diet and increased physical activity.”
> “While this study did not impact the strength or direction of the recommendation, additional research on pharmacotherapy for weight loss may further inform this recommendation in the future.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.3-2"></a>

### ATS guideline: comprehensive lifestyle intervention (strong), antiobesity pharmacotherapy evaluation (conditional), and bariatric surgery referral (conditional)

> “We recommend participation in a comprehensive lifestyle intervention program that includes a reduced-calorie diet, exercise/increased physical activity, and behavioral counseling rather than no program (strong recommendation, very low certainty in the estimated effects).”
> “For patients with OSA with a BMI greater than or equal to 27 kg/m2, whose weight has not improved despite participating in a comprehensive weight-loss lifestyle program, and who have no contraindications including no active cardiovascular disease, we suggest an evaluation for antiobesity pharmacotherapy (conditional recommendation, very low certainty in the estimated effects).”
> “For patients with OSA with a BMI greater than or equal to 35 kg/m2, whose weight has not improved despite participating in a comprehensive weight-loss lifestyle intervention program, and who have no contraindications, we suggest referral for bariatric surgery evaluation (conditional recommendation, very low certainty in the estimated effects).”

Source: [Hudgel et al. (2018)](https://academic.oup.com/ajrccm/article/198/6/e70/8498283)

<a id="topic-2.2.2.1.3-3"></a>

### ATS guideline: literature search dates and pharmacotherapies reviewed

> “Searching was conducted in July and August 2015 and then updated in February 2017 and February 2018.”
> “Our literature search identified three studies of patients with OSA that evaluated the effects of phentermine/topiramate ER (54), liraglutide (55), or orlistat (56).”

Source: [Hudgel et al. (2018)](https://academic.oup.com/ajrccm/article/198/6/e70/8498283)

<a id="topic-2.2.2.1.3-4"></a>

### ACP guideline: weight loss for all adults with overweight or obesity and OSA (strong recommendation, low-quality evidence)

> “RECOMMENDATION 1: ACP recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight. (Grade: strong recommendation; low-quality evidence)”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.3-5"></a>

### Tirzepatide label: indication for moderate to severe OSA in adults with obesity

> “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:”
> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### Tirzepatide label: dose escalation and OSA maintenance dosage

> “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
> “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose [see Dosage and Administration (2.2)].”
> “The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.”
> “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### Tirzepatide label: design of the OSA trials, AHI of at least 15 and BMI of at least 30

> “The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] ≥15) in patients with obesity (BMI ≥30 kg/m2) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration.”
> “Study 5 enrolled 234 adult patients with moderate to severe OSA and obesity who were unable or unwilling to use Positive Airway Pressure (PAP) therapy.”
> “Study 6 enrolled 235 adult patients with moderate to severe OSA and obesity who were on PAP therapy.”
> “The clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

### Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation

| Measure | Study 5 placebo (N = 120) | Study 5 ZEPBOUND MTD (N = 114) | Study 5 difference from placebo (95% CI) | Study 6 placebo (N = 114) | Study 6 ZEPBOUND MTD (N = 119) | Study 6 difference from placebo (95% CI) |
| --- | --- | --- | --- | --- | --- | --- |
| AHI change from baseline (events/hr) | “-5.3” | “-25.3” | “-20 (-25.8, -14.2)” | “-5.5” | “-29.3” | “-23.8 (-29.6, -17.9)” |
| Percent change in AHI from baseline | “-3” | “-50.7” | “-47.7 (-65.8, -29.6)” | “-2.5” | “-58.7” | “-56.2 (-73.7, -38.7)” |
| Percent of participants with ≥50% reduction in AHI | “19” | “61.2” | “42.8 (30.8, 54.8)” | “23.3” | “72.4” | “48.6 (36.6, 60.7)” |
| Percent with AHI <5 or AHI 5-14 and ESS ≤10 | “15.9” | “42.2” | “28.7 (18.3, 39.2)” | “14.3” | “50.2” | “33.2 (22.1, 44.3)” |

Source: [Eli Lilly Zepbound prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf)

> “Data from polysomnographic studies were scored centrally with the use of the American Academy of Sleep Medicine rule 1B for identification of hypopneas (which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-9"></a>

### SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”
> “All results are reported with the use of the treatment-regimen estimand unless otherwise specified.”
> “Overall, 82.9% of the participants completed the trial (91.5% in the tirzepatide groups and 74.4% in the placebo groups) and 79.7% adhered to the assigned regimen (87.6% in the tirzepatide groups and 71.9% in the placebo groups) (Fig. S3).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-10"></a>

### SURMOUNT-OSA: AHI change at week 52, efficacy estimand

> “For the efficacy estimand, the change in AHI at week 52 was −27.4 events per hour (95% CI, −31.6 to −23.2) with tirzepatide and −4.8 events per hour (95% CI, −9.3 to −0.3) with placebo, for an estimated treatment difference of −22.5 events per hour (95% CI, −28.7 to −16.4).”
> “For the efficacy estimand, the change in AHI at week 52 with tirzepatide was −30.4 events per hour (95% CI, −34.3 to −26.5) with tirzepatide and −6.0 events per hour (95% CI, −10.3 to −1.6) with placebo, for an estimated treatment difference of −24.4 events per hour (95% CI, −30.3 to −18.6).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-11"></a>

### SURMOUNT-OSA: percent change in body weight at week 52, treatment-regimen estimand

| Measure | Trial 1 tirzepatide | Trial 1 placebo | Trial 1 difference | Trial 2 tirzepatide | Trial 2 placebo | Trial 2 difference |
| --- | --- | --- | --- | --- | --- | --- |
| Percent change in body weight (95% CI) | “−17.7 (−19.0 to −16.3)” | “−1.6 (−2.9 to −0.2)” | “−16.1 (−18.0 to −14.2)” | “−19.6 (−21.0 to −18.2)” | “−2.3 (−3.8 to −0.9)” | “−17.3 (−19.3 to −15.3)” |

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-12"></a>

### AASM provider fact sheet: tirzepatide as part of comprehensive OSA care

> “Consider as part of comprehensive OSA care along with positive airway pressure (PAP) therapy, oral appliance therapy, or surgery as appropriate, not as a replacement for PAP. There is no head-to-head evidence to date that compares Zepbound with other OSA treatments.”
> “Reassess PAP needs as AHI improves along with weight loss; maintain long-term weight plan to sustain OSA benefit.”

Source: [American Academy of Sleep Medicine Zepbound provider fact sheet (2026)](https://aasm.org/wp-content/uploads/2026/04/ProviderFS_Zepbound_2026-DIGITAL-2.pdf)

<a id="topic-2.2.2.1.3-13"></a>

### AASM guideline: discussion of bariatric surgery referral for adults with BMI of at least 35 who are intolerant or unaccepting of PAP (strong)

> “Recommendation 2: We recommend that clinicians discuss referral to a bariatric surgeon with adults with OSA and obesity (class II/III, BMI ≥ 35) who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).”
> “The TF made a strong recommendation in favor of bariatric surgery referral based on moderate-quality evidence from 2 RCTs and 28 observational studies that showed clinically meaningful improvements in several critical outcomes, and the benefits of discussing referral over the harms of no treatment.”
> “Additionally, iron malabsorption, gastric ulcer, vitamin deficiency, bowel obstruction or leak, gastrointestinal reflux disorder, and gastric band slippage have been reported but the incidence of these is low.”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.3-14"></a>

### ERS guideline: bariatric surgery evaluation after an unsuccessful weight reduction programme (conditional recommendation, very low quality of evidence), AHI scoring rule not stated

> “In adult obese patients with OSA, we suggest bariatric surgery evaluation versus weight-reducing diet when weight has not improved despite participating in a comprehensive weight reduction programme and if there are no contraindications (conditional recommendation, very low quality of evidence).”
> “The difference between the change scores was −11.5 events·h−1 (95% CI −28.3–5.3 events·h−1), which was not statistically significant (p=0.18).”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
